In brief: Acrux, Meditech, Psivida
Tuesday, 03 May, 2005
Melbourne's Acrux (ASX: ACR) has Adam Watkinson as its chief scientific officer. Watkinson is currently manager of drug delivery research and project manager at UK pharmaceutical company ProStrakan .
Meditech Research's (ASX: MTR) Ian Nisbet is to present the company's business plans and product data at the Rodman & Renshaw Global Healthcare Conference in Paris on May 5.
pSivida Limited (ASX:PSD, NASDAQ:PSDV, Xetra:PSI) is to present the interim data from its Phase IIa BrachySil trial in patients with primary liver cancer to the European Society for Therapeutic and Radiation Oncology Conference in Budapest on May 5.
Psivida has reported that both patient cohorts from the Phase IIa trial show the product is safe and effective in prompting tumour regression.The final data is expected to be released in June.
Link between oestrogen and heart health found in women
Scientists found that oestrogen helps increase the ANXA1 protein, and when ANXA1 is missing, the...
Frequent nightmares accelerate aging, increase risk of death
Nghtmares independently predict faster biological aging and earlier mortality — even after...
Cardiac organoids bring hope for treating heart disease
Australian scientists have developed lab-grown, three-dimensional heart tissues known as cardiac...
